… larger randomized phase III setting. A randomized, open-label, parallel assignment
phase II … patients (100 estimated) with extensive-stage SCLC in September 2009 for first-line …

… In a randomized phase III trial, 610 patients with inoperable stage II or III non–small cell
lung cancer were randomly assigned to two different concurrent regimens (chemotherapy with …

… patients and the only agent for which phase III data exists in a large number of patients
with prior platinum therapy. In the first of two randomized phase III trials, median survival with …

… We conducted a global, randomized, placebo-controlled, phase II study in patients with …
A randomized phase III study evaluating erlotinib with or without onartuzumab in patients …

… stage small-cell lung cancer who had a complete response at distant disease sites, and a
complete or partial response locally, were randomly … Randomized phase III trial comparing …

… Clarke S, Boyer M, Millward M, et al: Phase II study of LY231514, a multi-targeted antifolate,
in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16::…

… This randomized phase II–III trial sought to evaluate the efficacy and safety of adding
bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell lung cancer (…

… Because there has been no comparative study of amrubicin with another single agent for
relapsed SCLC, we conducted this randomized phase II study to select the superior single …

… Amrubicin was approved in Japan in 2002 for SCLC and non–small-cell lung cancer and
is under evaluation in other countries. Two North American/European phase II studies 19,20 …

… In the area of cancer vaccine development, BEC2, an anti-idiotype vaccine targeting … cell
membrane of most small-cell lung cancer tumors, failed to show a survival benefit in a phase III …